Crinetics soars after Vertex agrees to buy drugmaker in $10 billion deal
06/07/2026 21:38
BUZZ-Crinetics soars after Vertex agrees to buy drugmaker in $10 billion deal ** Shares of Crinetics Pharmaceuticals CRNX.O more than double to $84.69 in extended trading
** Vertex Pharmaceuticals VRTX.O has agreed to acquire CRNX for $85.00 per share in cash for a total equity value of about $10 billion
** Shares of Vertex down 2.8% at $514.75 in extended trading
** The transaction was unanimously approved by both the companies' boards of directors and is anticipated to close in Q3 2026
** Up to last close, CRNX down ~10%, while VRTX up ~17% this year
(Reporting by Jaspreet Singh in Bengaluru)
((Jaspreet.Singh@thomsonreuters.com ; https://twitter.com/i_jass))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria